Circulating Insulin-like Growth Factors and Risks of Overall, Aggressive and Early-onset Prostate Cancer: a Collaborative Analysis of 20 Prospective Studies and Mendelian Randomization Analysis

Background: Previous studies had limited power to assess the associations of circulating insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) with clinically relevant prostate cancer as a primary endpoint, and the association of genetically predicted IGF-I with aggressive prostate cancer is not known. We aimed to investigate the associations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 concentrations with overall, aggressive and early-onset prostate cancer.

Methods: Prospective analysis of biomarkers using the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group dataset (up to 20 studies, 17 009 prostate cancer cases, including 2332 aggressive cases). Odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression. For IGF-I, two-sample Mendelian randomization (MR) analysis was undertaken using instruments identified using UK Biobank (158 444 men) and outcome data from PRACTICAL (up to 85 554 cases, including 15 167 aggressive cases). Additionally, we used colocalization to rule out confounding by linkage disequilibrium.

Results: In observational analyses, IGF-I was positively associated with risks of overall (OR per 1 SD = 1.09: 95% CI 1.07, 1.11), aggressive (1.09: 1.03, 1.16) and possibly early-onset disease (1.11: 1.00, 1.24); associations were similar in MR analyses (OR per 1 SD = 1.07: 1.00, 1.15; 1.10: 1.01, 1.20; and 1.13; 0.98, 1.30, respectively). Colocalization also indicated a shared signal for IGF-I and prostate cancer (PP4: 99%). Men with higher IGF-II (1.06: 1.02, 1.11) and IGFBP-3 (1.08: 1.04, 1.11) had higher risks of overall prostate cancer, whereas higher IGFBP-1 was associated with a lower risk (0.95: 0.91, 0.99); these associations were attenuated following adjustment for IGF-I.

Conclusions: These findings support the role of IGF-I in the development of prostate cancer, including for aggressive disease.

Citing Articles

Serum urea concentration and risk of 16 site-specific cancers, overall cancer, and cancer mortality in individuals with metabolic syndrome: a cohort study.

Wu E, Wei G, Li Y, Du M, Ni J BMC Med. 2024; 22(1):536.

PMID: 39548477 PMC: 11566152. DOI: 10.1186/s12916-024-03758-5.

Identifying causal relationships between 35 blood and urine biomarkers and urologic cancers: MR-meta combined with Bayesian colocalization Mendelian randomization analysis.

An W, Zhao C, Wang Y, Zhang Y, Qiao Z Discov Oncol. 2024; 15(1):617.

PMID: 39495393 PMC: 11534928. DOI: 10.1007/s12672-024-01493-0.

The risk of cancer among insulin glargine users in Lithuania: A retrospective population-based study.

Jonusas J, Drevinskaite M, Linkeviciute-Ulinskiene D, Ladukas A, Patasius A, Zabuliene L Open Med (Wars). 2024; 19(1):20241017.

PMID: 39434861 PMC: 11491771. DOI: 10.1515/med-2024-1017.

Associations of body composition measures with circulating insulin-like growth factor-I, testosterone, and sex hormone-binding globulin concentrations in 16,000 men.

Hynes M, Watling C, Dunneram Y, Key T, Perez-Cornago A Int J Obes (Lond). 2024; 48(12):1809-1817.

PMID: 39433891 PMC: 11584381. DOI: 10.1038/s41366-024-01633-0.

Estetrol Inhibits the Prostate Cancer Tumor Stimulators FSH and IGF-1.

Coelingh Bennink H, Roos E, Jeroen A van Moorselaar R, van Melick H, Somford D, Roeleveld T J Clin Med. 2024; 13(19).

PMID: 39408055 PMC: 11478095. DOI: 10.3390/jcm13195996.

References

Bowden J, Davey Smith G, Haycock P, Burgess S . Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016; 40(4):304-14. PMC: 4849733. DOI: 10.1002/gepi.21965. View

Wu L, Wang J, Cai Q, Cavazos T, Emami N, Long J . Identification of Novel Susceptibility Loci and Genes for Prostate Cancer Risk: A Transcriptome-Wide Association Study in Over 140,000 European Descendants. Cancer Res. 2019; 79(13):3192-3204. PMC: 6606384. DOI: 10.1158/0008-5472.CAN-18-3536. View

Lawlor D, Tilling K, Davey Smith G . Triangulation in aetiological epidemiology. Int J Epidemiol. 2017; 45(6):1866-1886. PMC: 5841843. DOI: 10.1093/ije/dyw314. View

Burgess S, Bowden J, Fall T, Ingelsson E, Thompson S . Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants. Epidemiology. 2016; 28(1):30-42. PMC: 5133381. DOI: 10.1097/EDE.0000000000000559. View

Giambartolomei C, Vukcevic D, Schadt E, Franke L, Hingorani A, Wallace C . Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014; 10(5):e1004383. PMC: 4022491. DOI: 10.1371/journal.pgen.1004383. View

Conti D, Darst B, Moss L, Saunders E, Sheng X, Chou A . Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021; 53(1):65-75. PMC: 8148035. DOI: 10.1038/s41588-020-00748-0. View

Burgess S, Thompson S . Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol. 2015; 181(4):251-60. PMC: 4325677. DOI: 10.1093/aje/kwu283. View

Holmes M, Richardson T, Ference B, Davies N, Davey Smith G . Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. Nat Rev Cardiol. 2021; 18(6):435-453. DOI: 10.1038/s41569-020-00493-1. View

Watts E, Fensom G, Smith Byrne K, Perez-Cornago A, Allen N, Knuppel A . Circulating insulin-like growth factor-I, total and free testosterone concentrations and prostate cancer risk in 200 000 men in UK Biobank. Int J Cancer. 2020; 148(9):2274-2288. PMC: 8048461. DOI: 10.1002/ijc.33416. View

10.

McKay J, Hung R, Han Y, Zong X, Carreras-Torres R, Christiani D . Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nat Genet. 2017; 49(7):1126-1132. PMC: 5510465. DOI: 10.1038/ng.3892. View

11.

Knuppel A, Fensom G, Watts E, Gunter M, Murphy N, Papier K . Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK Biobank. Cancer Res. 2020; 80(18):4014-4021. DOI: 10.1158/0008-5472.CAN-20-1281. View

12.

Palmer T, Sterne J, Harbord R, Lawlor D, Sheehan N, Meng S . Instrumental variable estimation of causal risk ratios and causal odds ratios in Mendelian randomization analyses. Am J Epidemiol. 2011; 173(12):1392-403. DOI: 10.1093/aje/kwr026. View

13.

Hemani G, Tilling K, Davey Smith G . Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 2017; 13(11):e1007081. PMC: 5711033. DOI: 10.1371/journal.pgen.1007081. View

14.

Schumacher F, Olama A, Berndt S, Benlloch S, Ahmed M, Saunders E . Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018; 50(7):928-936. PMC: 6568012. DOI: 10.1038/s41588-018-0142-8. View

15.

Yarmolinsky J, Wade K, Richmond R, Langdon R, Bull C, Tilling K . Causal Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization?. Cancer Epidemiol Biomarkers Prev. 2018; 27(9):995-1010. PMC: 6522350. DOI: 10.1158/1055-9965.EPI-17-1177. View

16.

Allard J, Duan C . IGF-Binding Proteins: Why Do They Exist and Why Are There So Many?. Front Endocrinol (Lausanne). 2018; 9:117. PMC: 5900387. DOI: 10.3389/fendo.2018.00117. View

17.

Hakuno F, Takahashi S . IGF1 receptor signaling pathways. J Mol Endocrinol. 2018; 61(1):T69-T86. DOI: 10.1530/JME-17-0311. View

18.

Watts E, Appleby P, Perez-Cornago A, Bueno-de-Mesquita H, Chan J, Chen C . Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies. Eur Urol. 2018; 74(5):585-594. PMC: 6195673. DOI: 10.1016/j.eururo.2018.07.024. View

19.

Wallace C . A more accurate method for colocalisation analysis allowing for multiple causal variants. PLoS Genet. 2021; 17(9):e1009440. PMC: 8504726. DOI: 10.1371/journal.pgen.1009440. View

20.

Travis R, Appleby P, Martin R, Holly J, Albanes D, Black A . A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. Cancer Res. 2016; 76(8):2288-2300. PMC: 4873385. DOI: 10.1158/0008-5472.CAN-15-1551. View